5 | AcidsIBA
03/2014
-
07/2010 |
3 | GemcitabineFDA Link
01/2021
-
10/2012 |
3 | LipidsIBA
09/2020
-
01/2010 |
3 | C-Reactive ProteinIBA
01/2017
-
05/2013 |
3 | Anti-Bacterial Agents (Antibiotics)IBA
10/2016
-
07/2011 |
3 | Proton Pump InhibitorsIBA
04/2013
-
05/2010 |
3 | Proteins (Proteins, Gene)FDA Link
03/2013
-
01/2011 |
3 | Capsules (Microcapsules)IBA
01/2013
-
06/2007 |
3 | CannabinoidsIBA
04/2011
-
05/2010 |
3 | CytokinesIBA
01/2011
-
01/2010 |
2 | MetalsIBA
06/2018
-
12/2015 |
2 | perfluoro- 2,2,2',2'- tetramethyl- 4,4'- bis(1,3- dioxolane)IBA
10/2016
-
03/2010 |
2 | Capecitabine (Xeloda)FDA Link
04/2015
-
10/2012 |
2 | mosaprideIBA
04/2013
-
03/2004 |
2 | Serotonin 5-HT4 Receptor AgonistsIBA
04/2013
-
03/2004 |
2 | Doxorubicin (Adriamycin)FDA LinkGeneric
01/2012
-
01/2011 |
2 | Antineoplastic Agents (Antineoplastics)IBA
04/2011
-
05/2010 |
2 | (3R)- ((2,3- dihydro- 5- methyl- 3- ((4- morpholinyl)methyl)pyrrolo- (1,2,3- de)- 1,4- benzoxazin- 6- yl)(1- naphthalenyl))methanone (WIN 55,212)IBA
04/2011
-
05/2010 |
2 | Cannabinoid Receptor AgonistsIBA
04/2011
-
05/2010 |
2 | Cannabinoid Receptors (Cannabinoid Receptor)IBA
01/2011
-
05/2010 |
2 | Pepsinogen A (Pepsinogen)IBA
03/2008
-
08/2007 |
1 | Glucose (Dextrose)FDA LinkGeneric
09/2022 |
1 | Biomarkers (Surrogate Marker)IBA
05/2022 |
1 | Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
10/2020 |
1 | Peptides (Polypeptides)IBA
07/2019 |
1 | Fluorescein-5-isothiocyanate (FITC)IBA
07/2019 |
1 | PlasticsIBA
06/2018 |
1 | MucinsIBA
01/2018 |
1 | Antifungal AgentsIBA
10/2016 |
1 | Indicators and Reagents (Reagents)IBA
05/2015 |
1 | Cisplatin (Platino)FDA LinkGeneric
04/2015 |
1 | PlatinumIBA
04/2015 |
1 | Rabeprazole (Aciphex)FDA Link
09/2014 |
1 | Intravenous Immunoglobulins (IVIG)FDA Link
06/2014 |
1 | Erythromycin (Erycette)FDA LinkGeneric
05/2014 |
1 | SilverIBA
01/2014 |